[International perspectives on essential drugs: the experience of Mexico and developing countries].
Explore the source record for details and available documents.
SEARCH · Search PubMed
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Conditions in developing countries are nowhere near what they should be to reap the benefits of modern biotechnology. Be that as it may, there are possibilities in which intelligent thinking and rational planning by the people concerned, combined with input from international agencies and national centres of excellence, can lead to potential economic gains. One possibility is the establishment of collaborative research on a regional basis to tackle common problems and to train each other's manpower in acquired skills. Similarity of circumstances would make these programmes more relevant and cost effective. To ensure the success of joint programmes in the local setting, foreign input in the form of finances, provision of critical laboratory materials, and expert advice in the selection of technically solvable problems becomes inevitable. Thus participation by the developed-country agencies and laboratories in the developing countries presents a purposeful pooling of efforts that will sow the seeds for sustainable development of the developing world. Given that, new technology would prove a boon and a blessing for humanity in general and for the developing world in particular.
The difficulties experienced in transfer of medical technology to developing countries are aggravated by partial and incomplete understanding of the cultural, social, economic, and institutional factors affecting technology development, transfer, dissemination and use. In this paper, it is argued that a more dynamic and comprehensive approach is needed for the analysis of these factors. Such an approach would provide the basis for linking existing information stemming from partial analyses of problems related to individual users, the health services or systems, and the technology itself. The starting point of any comprehensive analysis must be the structure of the society in which the technology is to be used. The value of a comprehensive analytical approach is illustrated by discussion of a medical technology still under development, a vaccine against malaria. This discussion further indicates that consideration of cultural, social, economic, and institutional factors in the developmental phases of a technology can contribute to ensuring acceptability and sustainability of the technology under the multifaceted conditions in which it is to be used.
Explore the source record for details and available documents.